When you send for molecular studies for polycythemia vera, what are the mutations that predict increased cardiovascular risk?
How do you use this information in clinical practice?
1 Answer
Mednet MemberInvited Expert
Hematology · Johns Hopkins University
Answered on
This is a very prescient question since arterial and venous thrombosis are frequent events in MPN patients who have polycythemia vera (PV) and these events can precede the diagnosis of PV by several years. Most importantly, we also now know that just having a JAK2 V617F mutation without any clinical...
Join for free or sign in to see the full answer